Related Experiment Videos
Does digoxin still have a role in congestive heart failure?
1Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi.
Insights
Digoxin
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) treatment is evolving.
- The role of digoxin in CHF management is under review.
Purpose of the Study:
- To evaluate the efficacy of digoxin in various forms of congestive heart failure.
- To provide guidance on individualized digoxin treatment strategies.
Main Methods:
- Review of large randomized trials.
- Analysis of limited data for specific patient subgroups.
- Assessment of clinical recommendations for digoxin use.
Main Results:
- Digoxin remains a primary choice for atrial fibrillation in CHF.
- Digoxin shows benefits in CHF with systolic dysfunction (not reducing mortality).
- Efficacy is limited in CHF due to left to right shunts and absent in diastolic dysfunction.
Conclusions:
- Digoxin's benefit in CHF is condition-specific.
- Treatment decisions regarding digoxin require individual patient assessment.
- Not recommended for premature infants with patent ductus and CHF.
Abstract:
The role of digoxin in the treatment of congestive heart failure is (CHF) being questioned. Digoxin continues to be the drug of choice for patients with atrial fibrillation in CHF. Large randomised trials have shown that digoxin (in addition to ACE inhibitors and diuretic) is beneficial in CHF due to systolic dysfunction, although it does not reduce mortality. Limited data suggest that digoxin benefit some, but not all patients with CHF due to left to right shunts. Digoxin does not benefit CHF due to diastolic dysfunction and it is not routinely recommended for prematures with patent ductus and CHF. The treatment with digoxin should be individualised.